Comments
Lupin has received the US health regulator’s approval to market a generic version of Sanofi Aventis’ Rifadin capsules, used to treat tuberculosis, in the American market.
The company’s US-based subsidiary Lupin Pharmaceuticals Inc has received final approval from the US Food and Drug Administration (USFDA) for its Rifampin capsules in 150 mg and 300 mg strengths, Lupin Ltd said in a statement today.
Rifampin capsules are indicated for the treatment of all forms of tuberculosis. As per the IMS sales data, Rifadin capsules had annual US sales of around $18.5 million.
“Lupin is one of the pioneers in the fight against tuberculosis and holds global leadership positions in the anti-TB segment,” the company said.
Lupin shares ended at Rs 790.30 a piece on the BSE, up 1.55 per cent from their previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.